Details

Autor(en) / Beteiligte

• Hermsen, B.B.J
• Verheijen, R.H.M
• Menko, F.H
• Gille, J.J.P
• van Uffelen, K
• Blankenstein, M.A
• Meijer, S
• van Diest, P.J
• Kenemans, P
• von Mensdorff-Pouilly, S

Titel

Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation

Ist Teil von

• European journal of cancer (1990), 2007-07, Vol.43 (10), p.1556-1563

Ort / Verlag

Oxford: Elsevier Ltd

Erscheinungsjahr

2007

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Introduction Breast cancer patients with early disease and a natural humoral response to MUC1 have a favourable prognosis, suggesting a possible role of MUC1 antibodies (ab) in controlling haematogenous tumour dissemination and outgrowth. The aim of the study was to evaluate humoral immune responses to MUC1 in women at hereditary high risk of breast cancer to investigate whether this immune response could play a role in the prevention of disease. Materials and methods CA15.3 (U/mL), and IgG and IgM ab to MUC1 (arbitrary units per mL, Arb-U/mL) were measured in serum samples obtained from 422 women at hereditary high risk of breast/ovarian cancer, of whom 127 BRCA1/2 carriers, attending the Familial Cancer Clinic of the VU University Medical Centre, and from 370 age-matched healthy controls. Serum samples obtained from women who developed breast cancer ( N = 12) or breast cancer recurrence ( N = 17), and from women who underwent prophylactic mastectomy ( N = 12) and had no breast lesions were also tested. Results CA15.3 ranked significantly higher in mutation carriers than in controls ( P = 0.03). MUC1 IgG ab levels ranked significantly lower in BRCA1/2 mutation carriers than in controls ( P = 0.003). MUC1 IgG levels were not significantly different ( P = 0.53) between women who developed primary breast cancer (median 0.72 Arb-U/ml, range 0.52–2.44 Arb-U/ml) and women who underwent prophylactic mastectomy and had no breast lesions (median 1.04 Arb-U/ml, range 0.43–2.88 Arb-U/ml). Conclusion Serum levels of natural IgG ab to MUC1 are lower in BRCA1/2 mutation carriers than in healthy controls. Furthermore, in contrast to previous results in women with sporadic breast cancer, no elevated MUC1 IgG ab were seen in women at hereditary high risk who developed breast cancer. Prophylactic immunotherapy with MUC1 substrates may be a strategy to reduce the risk of breast cancer in BRCA1/2 mutation carriers, strengthening tumour immune surveillance.